ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Areej El-Jawahri, MD, and Eric Roeland, MD, FAAHPM, on Quality of Life and Satisfaction With Care

Eric Roeland, MD, FAAHPM, of the University of California, San Diego Moores Cancer Center, and Areej El-Jawahri, MD, of Massachusetts General Hospital, discuss two important studies on early palliative care and the use of anamorelin in advanced NSCLC with cachexia.

Supportive Care

Symptom Management

Palliative Care

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data

Daniel A. Vorobiof, MD, of the Sandton Oncology Centre, and Bernardo Leon Rapoport, MD, of The Medical Oncology Centre of Rosebank, discuss the first study to evaluate the efficacy and safety of a single dose of intravenous fosaprepitant. The use of this NK1 inhibitor and another (rolapitant) in a second study discussed may change the management of chemotherapy-induced nausea and vomiting and improve quality of life for patients (Abstracts 9629 and 9615).

Bladder Cancer

Prostate Cancer

Derek Raghavan, MD, PhD

Derek Raghavan, MD, PhD: Roundup of Clinical Trial Results on Genitourinary Cancers

Derek Raghavan, MD, PhD, of the Levine Cancer Institute, gives his insights into key genitourinary cancer clinical trials presented at the 2015 ASCO Annual Meeting and his thoughts on where the research is headed.

Global Cancer Care

Gynecologic Cancers

Eduardo Cazap, MD, PhD and James O. Armitage, MD

Eduardo Cazap, MD, PhD, and James O. Armitage, MD, on The Current State of Cancer Research and Treatment: The Latin American Perspective

Eduardo Cazap, MD, PhD, of the Latin American & Caribbean Society of Medical Oncology, and James O. Armitage, MD, of the University of Nebraska Medical Center, discuss oncology from an international point of view.

Cost of Care

Leonard Saltz, MD

Leonard Saltz, MD, on Issues of Value in Melanoma Treatment

Leonard Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.

Mar

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Areej El-Jawahri, MD, and Eric Roeland, MD, FAAHPM, on Quality of Life and Satisfaction With Care

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data

Derek Raghavan, MD, PhD: Roundup of Clinical Trial Results on Genitourinary Cancers

Eduardo Cazap, MD, PhD, and James O. Armitage, MD, on The Current State of Cancer Research and Treatment: The Latin American Perspective

Leonard Saltz, MD, on Issues of Value in Melanoma Treatment

Advanced RCC After Immunotherapy Belzutifan Plus Lenvatinib or Cabozantinib

Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence

Extended Endocrine Therapy in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer

Stereotactic vs Whole-Brain Radiation for Patients With Brain Metastases

Skin Fluorescent Imaging Shows High Sensitivity, Specificity for Discriminating Melanoma Lesions